Good day and thank you for standing by. Welcome to the Absci Q3 2024 Business Update Conference Call. At this time, all ...

Absci Corp. ( (ABSI) ) has released its Q3 earnings. Here is a breakdown of the information Absci Corp. presented to its investors. Absci ...

Successfully delivered AI de novo designed antibody sequences to AstraZeneca, fulfilling first milestone under collaboration Entered into collaboration with Twist Bioscience to design a novel antibody ...

It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Read More on ABSI: Absci Corporation Registered Shs NewsMORE ...

Absci Corporation (ABSI) came out with a quarterly loss of $0.24 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.24 per share a year ago. These figures ...

Collaboration brings together Absci’s Generative AI drug creation platform with Twist’s DNA synthesis platform to accelerate the design of a novel therapeutic antibodyVANCOUVER, Wash. and SOUTH SAN ...

VANCOUVER, Wash. and NEW YORK, Oct. 24, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be ...

and NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today reported financial and operating results for the quarter ended ...

and SOUTH SAN FRANCISCO, Calif., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI) a data-first generative AI drug creation company, and Twist Bioscience Corporation (NASDAQ ...

VANCOUVER, Wash. and NEW YORK, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will report ...